Jeremiah Rhoads

2077 Ventures | Abaka AI | Ex-DB, GS, SMBC

📍 United States🔄 Updated September 2026💼 8 investments📅 1 years investing🗓 Last invested Jan 2026
VC🌍 United StatesInvested this year
8
Total investments
5
Early stage
2
Mid stage
0
Late stage
1y
Years active

Portfolio

8 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor
Jan 2026
Im an AI superconnector that makes thoughtful introductions. DM me your email and phone number to get started 💬
Investor
2026
World models and simulation infrastructure for physical AI.
Investor
2026
The AI Biology company.
Investor
2026
Odyssey is an AI lab pioneering general world models: causal, multimodal systems that learn to understand and simulate the world. This foundational technology promises to revolutionize robotics, science, healthcare, education, gaming, and beyond.
Investor
Nov 2025
Founded in 2025, AmendX is a healthcare technology company focused on restoring financial stability to providers by fixing one of the most broken parts of the healthcare system: insurance claim denials. Built at the intersection of artificial intelligence and revenue cycle operations, AmendX develops software that learns how individual insurance payors behave and deploys AI agents to execute the workflows required to overturn denied medical claims. Rather than relying on generic denial management tools, the AmendX platform trains on real claims, denials, and appeals data to understand the patterns, documentation requirements, and appeal strategies unique to each insurer. Using this intelligence, the system orchestrates specialized AI agents that analyze denied claims, assemble supporting documentation, generate insurer-specific appeals, and manage the submission and follow-up process required to secure reimbursement. Through a secure, HIPAA-compliant infrastructure, AmendX integrates with provider revenue cycle workflows while automating one of the most resource-intensive operational tasks in healthcare: denial recovery. The platform is designed to adapt as payor rules evolve, continuously improving its appeal strategies and execution through real-world feedback. The company’s early team includes engineers, healthcare operators, revenue cycle specialists, and AI researchers dedicated to rebuilding the balance of power between providers and insurers. With expertise spanning medical coding, utilization management, payor policy analysis, and agentic AI systems, AmendX is developing the next generation of provider-side financial infrastructure. AmendX is currently in its pre-seed/seed fundraising phase as the company expands its payor intelligence models, deepens partnerships with oncology clinics and revenue cycle organizations, and prepares for broader deployment across health systems nationwide.
Investor
2025
Understand the Universe. We are a team of AI technologists and business leaders on a mission to build AI systems that can help humanity understand the world better. https://x.ai/careers
Investor
2025
Real world. Real intelligence.
Investor
2025
World Labs is a spatial intelligence company building Large World Models (LWMs) to perceive, generate, and interact with the 3D world. We aim to lift AI models from the 2D plane of pixels to full 3D worlds – both virtual and real – endowing them with spatial intelligence as rich as our own. We believe that humans are innovative, curious, and creative; science and technology are both manifestations and drivers of these impulses. Propelling AI forward with spatial intelligence will also propel forward both individuals and humanity as a whole. Toward this goal, World Labs will develop spatially intelligent LWMs that can understand and reason about the 3D world from images and other modalities. Over time, we expect to train increasingly powerful models with broader capabilities that can be applied in a variety of domains, working alongside people. These are ambitious goals, so we are building an ambitious company to tackle them. Our team, led by co-founders Fei-Fei Li, PhD; Justin Johnson, PhD; Christoph Lassner, PhD; and Ben Mildenhall, PhD, has a strong research background, but we are not motivated by exploration for its own sake. Instead, we believe that now is a unique moment where rapid scientific progress has thinned the barrier between research and applications. We aim to seize this opportunity, focusing on the entire throughline from research to engineering to product to people. We are bringing together the most formidable slate of pixel talent ever assembled, creating a tight feedback loop between our spatially intelligent foundation models and products that will empower our users. We invite you to learn more about joining our fast-growing team.
Experience · 13 entries
All (13)
Investments (8)
2026
Investor
Jan 2026
Im an AI superconnector that makes thoughtful introductions. DM me your email and phone number to get started 💬
Investor
2026
World models and simulation infrastructure for physical AI.
Investor
2026
The AI Biology company.
Investor
2026
Odyssey is an AI lab pioneering general world models: causal, multimodal systems that learn to understand and simulate the world. This foundational technology promises to revolutionize robotics, science, healthcare, education, gaming, and beyond.
2025
Senior Investment Associate & Operator
Dec 2025
2077 Ventures is built around the belief that early-stage frontier companies need more than funding--they need deep technical and operational leverage. We invest globally in Generative AI, AI Agents, Robotics, and Autonomous Systems. Leveraging the 2077AI community and network, we provide far more than capital access to domain experts, high-quality data and compute resources, go-to-market channels, and a trusted peer community. We partner with frontier researchers, entrepreneurs, and engineers at pre-seed and seed stages and stay hands-on through product validation, technical hiring, and early customer introductions. Our mission is simple: accelerate the path from breakthrough research to real-world impact.
Show all 13 entries ↓
Investment activity
2025–2026 · 8 investments
2025420264
Recent (last 2 years)Earlier